 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PURCHASE, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the Company or Cognition ) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...

Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the Company or Cognition ) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...

Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024

Cognition Therapeutics (NASDAQ:CGTX - Get Free Report)s stock had its "buy" rating restated by investment analysts at B. Riley in a research note issued on Thursday, Benzinga reports. They...

B. Riley Reiterates "Buy" Rating for Cognition Therapeutics (NASDAQ:CGTX)

Q4 2023 Cognition Therapeutics Inc Earnings Call Transcript

- Topline Results from SHINE Study in Mild-to-Moderate Alzheimer's Expected mid-2024 -- On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB in 2H 2024 - - 1Q 2024 Capital...

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

Cognition Therapeutics reports FY results...

Cognition Therapeutics reports FY results

A Preview Of Cognition Therapeutics's Earnings

Conference Call and Live Audio Webcast Scheduled for March 26, 2024PURCHASE, N.Y., March 15, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience...

Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results

The Dow Jones index closed lower by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and...

Cognition Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying

PURCHASE, N.Y., March 14, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. ( Cognition, the Company or We ) (Nasdaq: CGTX), a clinical stage company developing product candidates designed...

Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock

Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.

Volume (M)	116,813.00
52-Wk High	$3.49
52-Wk Low	$0.9001

CGTX Cognition Therapeutics Inc

About

Feed

News

Earnings

Fundamentals